Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)
NIH supports R61/R33 research and preclinical development of highly efficacious malaria vaccines, including platform and formulation innovation with potential relevance to other mosquito-borne diseases, but not clinical trials.
⚑ Clinical trials not allowed. · Foreign organizations are eligible, but applications involving foreign subawards/subcontracts are noncompliant and will not be considered. · Foreign components are allowed. · No award ceiling listed in the notice.
This is biomedical vaccine R&D and preclinical development, which is far outside IPPRA’s social-behavioral, survey, risk, and policy-evaluation portfolio. The public-health-security framing is too indirect to make this a plausible PI-level fit for any named team member.
JUDGED AGAINST THE ROSTER'S PUBLICATION DOSSIER · GPT-5.4-MINI · 2026-10-14
Unit fits — one characterization, each unit's own rules
| Physical Sciences & Engineering (demo) | 70 strong | technical depth: substantial; funds applied research |
| IPPRA | 45 partial | portfolio topics: public_health, environment; social/behavioral work is none; funds applied research; biomedical core — IPPRA health lane is communication/crisis/policy (capped); capped at 45 (limited social-science role) |
| Tom Love Innovation Hub | 45 partial | funds applied research; prototyping/demonstration stage; deep-tech content |
Description
The purpose of this notice of funding opportunity (NOFO) is to support research and/or preclinical development of highly efficacious vaccines against malaria - one of the deadliest mosquito-borne diseases - by capitalizing on recent technological innovations, particularly in structure-based immunogen design, improved formulations, and combination vaccines. The goal is to achieve long-lasting, highly effective protection that can save lives, strengthen public health security in the United States, and serve as a model for, or are potentially effective against, other mosquito-borne diseases.
Eligibility
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibilityForeign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16.8 Collaborative International Research Awards.Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.
Apply
View on Grants.gov → CONTACT: National Institutes of Health <MalariaandOtherMosquitoBorneDiseases@mail.nih.gov>
Proposal brief SEE AN EXAMPLE →
A one-page internal memo: fit assessment, submission requirements, document scaffold, and next steps dated back from the deadline — tailored to your project idea if you add one.
Proposal shell · National Institutes of Health conventions SEE AN NIH EXAMPLE →
Funder-faithful document skeletons — National Institutes of Health's document set with section headings, page limits, reviewer guidance, and writing prompts; add a project idea to get [DRAFT] starter bullets. Download as .md for Word or Overleaf.